selected publications
-
academic article
-
Risk factors for blood stream infections in multiple myeloma: A population‐based study of 1154 patients in Denmark.
European Journal Of Haematology.
101.
2018
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
PLoS ONE.
12.
2017
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Blood.
127.
2016
Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study.
European Journal Of Haematology.
97.
2016
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.
Clinical Cancer Research.
21.
2015
High‐dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma.
British Journal of Haematology.
171.
2015
-
dataset
-
Baseline characteristics for the entire cohort..
public-library-of-science.
2017
Immunoparesis and association to OS and PFS in different age groups..
public-library-of-science.
2017
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
public-library-of-science.
2017
Multivariable analysis of both qualitative and quantitative immunoparesis as risk factors for OS and PFS in all patients..
public-library-of-science.
2017
Multivariable analysis of factors for OS..
public-library-of-science.
2017
Multivariable analysis of factors for PFS..
public-library-of-science.
2017